Clinical Trial Update: Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) [Phase 2]

View source ↗

Summary

Completed Phase 2 study evaluating cabozantinib in metastatic castration-resistant prostate cancer (mCRPC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED